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Abstract
Prostaglandin E2 (PGE2) is a well-known inflammatory mediator that enhances the excitability of
DRG neurons. Homomeric P2X3 and heteromeric P2X2/3 receptors are abundantly expressed in
dorsal root ganglia (DRG) neurons and participate in the transmission of nociceptive signals. The
interaction between PGE2 and P2X3 receptors has not been well delineated. We studied the
actions of PGE2 on ATP-activated currents in dissociated DRG neurons under voltage-clamp
conditions. PGE2 had no effects on P2X2/3 receptor-mediated responses, but significantly
potentiated fast-inactivating ATP currents mediated by homomeric P2X3 receptors. PGE2 exerted
its action by activating EP3 receptors. To study the mechanism underlying the action of PGE2, we
found that the adenylyl cyclase activator, forskolin and the membrane-permeable cAMP analogue,
8-Br-cAMP increased ATP currents, mimicking the effect of PGE2. In addition, forskolin occluded
the enhancement produced by PGE2. The protein kinase A (PKA) inhibitors, H89 and PKA-I
blocked the PGE2 effect. In contrast, the PKC inhibitor, bisindolymaleimide (Bis) did not change
the potentiating action of PGE2. We further showed that PGE2 enhanced α,β-meATP-induced
allodynia and hyperalgesia and the enhancement was blocked by H89. These observations suggest
that PGE2 binds to EP3 receptors, resulting in the activation of cAMP/PKA signaling pathway and
leading to an enhancement of P2X3 homomeric receptor-mediated ATP responses in DRG
neurons.
Background
ATP plays a prominent role in nociception. Its application
onto human skin elicits pain [1,2]. Injection of ATP into
the rat hindpaw reduces paw withdrawal latencies and
produces flinching and writhing behaviors [3-6]. Recent
studies of purinergic receptors in primary sensory dorsal
root ganglion (DRG) neurons demonstrate that ATP gives
rise to nociception by activating P2X receptors in primary
sensory DRG neurons [7-9]. In situ hybridization assay
indicates that P2X2-P2X6 mRNAs are present in DRG neu-
rons [10]. P2X2 and P2X3 receptors are the major receptor
types selectively expressed in peripheral and central termi-
nals and the somata of DRG neurons [11-14]. These neu-
rons are small (diameter d < 25 µm) and medium (25 < d
< 40 µm) in size, bind isolectin B4 and express vanilloid
TRPV1 receptors [15-18]. The importance of P2X3-con-
taining receptors in nociception is further confirmed by
the findings that nociceptive behaviors become greatly
diminished in P2X3 knock-out mice [19,20] and in ani-
mals treated with P2X3 antisense oligonuclotides [21],
small interfering RNA (siRNA) [22] or the specific P2X3
antagonist, A-37491 [23]. Electrophysiological studies
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indicate that ATP produces large inward currents by acti-
vating P2X3 homomeric and P2X2/3 heteromeric recep-
tors, thus evoking depolarization in small and medium
DRG neurons [11,13,14,24,25]. In the spinal dorsal horn,
ATP, released from the central terminals of DRG neurons,
acts on presynaptic P2X receptors to promote AMPA
receptor-mediated synaptic transmission in nociceptive
pathways [26-30]
An important characteristic of P2X3 receptor-mediated
responses is its sensitivity to tissue and nerve injury. Noci-
ceptive behaviors produced by ATP become greatly
enhanced after inflammation [24] and nerve injury [31-
33]. An increase in P2X3 receptor-mediated responses is
one of the major reasons for the enhancement [11,31].
We found that the ATP currents in DRG neurons isolated
from rats with inflammation or nerve injury are 2–3 fold
larger [11,31]. The mechanisms responsible for the
increase include upregulation of P2X3 receptors [11],
enhancement of trafficking of P2X3 receptors toward the
membrane [31] and activation of calmodulin protein
kinase II [34]. The chemical mediator prostaglandin E2
(PGE2) is released during inflammation and sensitizes
peripheral terminals of DRG neurons [35,36]. It increases
capsaicin-evoked currents [37,38], promotes the release of
substance P and CGRP from sensory neurons [39,40]. In
the spinal cord, PGE2 dis-inhibits dorsal horn neurons by
blocking inhibitory glycinergic synaptic responses
[41,42]. PGE2 was found to enhance α,β-elicited nocicep-
tive behaviors in rats [3]. The interaction between PGE2
and purinergic receptors has not been thoroughly investi-
gated. Studying the action of PGE2 on ATP currents in
DRG neurons, we found that PGE2 increases P2X3-recep-
tor mediated ATP currents. Protein kinase A (PKA) medi-
ates the potentiating action of PGE2.
Results
PGE2 potentiates P2X3 receptor-mediated ATP responses
We first determined the effects of PGE2 on ATP or its ana-
log, α,β-meATP-activated currents in DRG neurons. Only
small (cross sectional area < 600 µm2) and medium (600–
1200 µm2) cells, which are known to mediate the trans-
mission of nociceptive signals [43], were used for the
study. Application of 10 µM ATP or α,β-meATP at a hold-
ing potential of -60 mV elicited large inward currents in
more than 80% of the neurons tested (Fig. 1A). The fast
ATP or α, β-meATP-evoked currents are mediated by P2X3
receptors because α,β-meATP activates only P2X1 and
P2X3 receptors [7] and the antagonist, A-317491, which
acts specifically on P2X3 receptors [23], abolished both
current responses (Fig. 1A). PGE2 (up to 100 µM), by
itself, did not evoke any membrane currents (n = 6, data
not shown). However, PGE2 (1 µM, 2 min application)
enhanced the peak amplitude of both fast-inactivating
ATP- and α,β-meATP-evoked currents (Fig. 1B). These
results suggest that PGE2 potentiates homomeric P2X3
receptor-mediated responses.
To further validate this conclusion, the effects of PGE2 on
P2X3 receptor-mediated currents were studied in detail.
As described in our previous study [11], homomeric P2X3
and heteromeric P2X2/3 receptors are the major P2X
receptors expressed in DRG neurons. The current
responses can be categorized based on their kinetics of
inactivation as fast, slow, and mixed responses. Fast-inac-
tivating currents are mediated by homomeric P2X3 recep-
tors, slow-inactivating currents by heteromeric P2X2/3
receptors and mixed currents by both homomeric P2X3
and heteromeric P2X2/3 receptors [11,13]. We found that
PGE2 (1 µM) potentiated the peak amplitude of fast-inac-
tivating ATP currents in 63% (72 out of 114) of the neu-
rons tested (Fig. 1C). PGE2 had no effects on fast ATP
currents in 22% of cells and reduced fast ATP responses in
the rest 15% of cells (IATP (with PGE2)/IATP = 0.57 ± 0.08,
n = 17) (data not shown). Only the potentiating effects of
PGE2 on fast-inactivating ATP currents were investigated
in detail. PGE2 did not alter slow-inactivating ATP cur-
rents (Fig. 1C). For mixed ATP responses, PGE2 increased
the peak amplitude of the currents (IATP (with PGE2)/IATP
= 1.56 ± 0.08, n = 6), while it had no effect on the steady-
state currents (Fig. 1C). These results suggest that PGE2
acts on the homomeric P2X3 receptors, but not on the
heteromeric P2X2/3 receptors.
The characteristics of PGE2 actions on fast-inactivating 
ATP currents
The time course of PGE2 (1 µM) effects was then studied
(Fig. 2A). ATP (10 µM) was repeatedly applied to the
tested cell every two min, a period that allowed P2X3
receptors to recover from inactivation sufficiently to give
consistent current responses [11,44]. Two minutes after
PGE2, fast ATP currents were increased by 48%, reaching
a saturating value 10 min later. The enhancing effect was
maintained at the peak level for another 4–6 min and
then started to decay. Thus, the action of PGE2 on the fast-
inactivating ATP currents desensitizes. Vehicle (0.1%
DMSO) had no effect on the fast ATP currents (Fig. 2B).
We chose to measure currents following a brief (2 min)
application of PGE2 (1 µM) in most experiments because
the application period allowed the potentiating effects of
PGE2 to reach a sufficiently high level and to dissipate
within 4 min.
The PGE2 effects on the kinetics of ATP currents were
examined. The activation time (Ta) of the fast current
response was calculated by measuring the duration
between 10 and 90% of the peak value. The inactivationMolecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
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Enhancement of fast-inactivating ATP currents by PGE2 Figure 1
Enhancement of fast-inactivating ATP currents by PGE2. 
(A) PGE enhances P2X3 receptor-mediated ATP currents. α,β-meATP and ATP evoked similar fast-inactivating currents. Both 
currents were blocked by the specific P2X3 antagonist, A-317491. 
(B) In the same cell, PGE2 potentiated α,β-meATP- and ATP-evoked currents similarly. Iαβ-meATP (PGE2)/Iαβ-meATP = 1.47 ± 
0.07, IATP (PGE2)/IATP = 1.54 ± 0.06 (* P < 0.05, n = 8). 
(C) Homomeric P2X3 receptors mediate the action of PGE2. (Left) A 2 sec ATP (10 µM) pulse elicited fast-inactivating (Fast), 
slow-inactivating (Slow) and mixed ATP currents in normal cells. Membrane was held at -60 mV. The currents were obtained 
from three different cells. (Right) After a 2-min application of PGE2 (1 µM), the fast ATP current was potentiated but the slow 
ATP current did not change. For the cell exhibiting mixed responses, PGE2 enhanced the peak, but not the steady state ATP 
currents. Bar graphs show the pooled data. PGE2 increased the peak amplitude of both fast-inactivating ATP currents [IATP 
(PGE2)/IATP = 1.46 ± 0.04 (n = 72)] and mixed ATP currents [IATP (PGE2)/IATP = 1.56 ± 0.08 (n = 6)] (* P < 0.05), which were 
mediated by homomeric P2X3 receptors. On the other hand, PGE2 had no effect on P2X2/3 receptor-mediated slow currents.Molecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
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Characteristics of PGE2 actions Figure 2
Characteristics of PGE2 actions. 
(A) Time course of PGE2 effects on fast ATP currents. ATP pulses were applied to the recorded cell every 2 min. After ATP 
responses reached a steady state, 1 µM PGE2 was applied to the bath. The fast ATP response was increased by 48% [IATP (with 
PGE2)/IATP = 1.48 ± 0.07, n = 6] two min later and the increase reached a peak level [IATP (with PGE2)/IATP = 1.90 ± 0.11] 10 
min after PGE2 application. Numbers in the graph correspond to the original traces shown above. 
(B) Bar graphs are the pooled data from 5 cells (* P < 0.05). 
(C) PGE2 does not change the affinity of ATP for P2X3 receptors. Fast ATP currents were measured at different ATP concen-
trations in control and in 1 µM PGE2. For the purpose of normalization among cells, the responses to 10 µM ATP in control 
solution in all of the cells were measured. Each data point was obtained from studies of 4–6 cells. The data points at 0.01 and 
0.1 µM ATP for control and PGE2 groups overlapped. The dose-response curves were fit by the Hill equation with Hill coeffi-
cient = 1. For control, EC50 = 2.02 ± 0.4 µM. For PGE2, EC50 = 2.77 ± 0.58 µM. PGE2 treatment does not alter ATP affinities 
for P2X receptors, although it greatly enhances peak ATP responses.Molecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
Page 5 of 13
(page number not for citation purposes)
time constants (τ1in and τ2in) were obtained by fitting the
inactivating phase of the current with a sum of two expo-
nentials. The changes in Ta, τ1in and τ2in were not signifi-
cantly different after PGE2 treatment (Table 1), suggesting
that PGE2 does not alter the kinetics of the fast-inactivat-
ing ATP currents.
We then determined whether PGE2 changes the EC50 of
ATP for P2X3 receptors. Dose-responses of ATP responses
in the absence and presence of PGE2 (1 µM) were exam-
ined (Fig. 2C). ATP, at 200 µM, elicited maximal ATP cur-
rents in both cases, although the level of maximal
response in PGE2 was 1.55-fold larger. Dose-response
curves were fit with the Hill equation. The EC50 was 2.02
± 0.4 µM in control and 2.77 ± 0.58 µM in PGE2 treated
cells. Thus, the EC50 of ATP for P2X3 receptors was not sig-
nificantly changed by PGE2. We conclude that the poten-
tiation of ATP responses by PGE2 is not due to a change
in the apparent affinity of ATP for P2X3 receptors.
EP3 receptors mediate the potentiating effect of PGE2
The prostanoid receptors (EP1-EP4) that mediate the
potentiating effects of PGE2 (Fig. 3) were determined. The
selective EP1 antagonist, SC-19220 [45], at 1 or 10 µM,
could not block the enhancing effects of PGE2, suggesting
that EP1 is not likely to be involved. Because no specific
antagonists for EP2 and EP3 were readily available, ago-
nists (butaporst for EP2 and sulprostone for EP3) were
used. The selective EP2 agonist, butaporst [46], at either 1
or 10 µM, did not affect ATP currents. In contrast, the EP3
agonist, sulprostone, at 0.1, 1, 10 µM, progressively
potentiated ATP responses, mimicking the effect of PGE2.
Although sulprostone also has a low affinity for EP1
receptors [45,46], the inability of the EP1 antagonist, SC-
19220 on sulprostone action has led us to conclude that
EP3 receptors mediate the effects of PGE2. Due to the lack
of proper agonists and antagonists, the involvement of
EP4 receptors was not studied.
PGE2 potentiation is mediated by PKA
Since PKA is known to participate in the actions of PGE2,
its role in the potentiation of ATP responses was studied.
We first studied that action of the adenylyl cyclase activa-
tor, forskolin and a membrane-permeable cAMP ana-
logue, 8-Br-cAMP on P2X3-receptor mediated currents.
Both forskolin and 8-Br-cAMP increased ATP currents,
mimicking the action of PGE2 (Figs 4A and 4B). To make
sure that PGE2 used the same signaling pathway as forsko-
lin, an occlusion experiment was performed. After forsko-
lin effect on ATP currents was established, PGE2 was then
applied to the cell (Fig. 4C). PGE2 no long could increase
ATP currents in the presence of forskolin. The results sug-
gest an involvement of cAMP/PKA. We then studied the
effect of a membrane-permeant PKA inhibitor, H89, on
the enhancing effect of PGE2. We first made sure that the
tested cell responded to PGE2 and then perfused H89 (1
µM) onto the recorded cell (Fig. 5A). In the presence of
H89 (1 µM), ATP responses declined somewhat. After 10
min pretreatment with H89, PGE2 no longer could
enhance ATP currents (Figs. 5A and 5D), suggesting that
PKA is involved in the modulatory action of PGE2. To
confirm the conclusion, we studied the effect of a specific
membrane impermeant PKA inhibitor, PKA-I, on the
PGE2 action (Fig. 5B). PKA-I was perfused into the cell
through a patch electrode. In order to measure PGE2
potentiation before PKA-I reached the cell interior, patch
electrodes of small tips (electrode resistance = 7–8
Mohm) were used to slow the intracellular perfusion of
PKA-I. In the presence of PKA-I, the potentiating effect of
PGE2 was completely blocked (Figs. 5B, D), confirming
that cAMP/PKA signaling is involved in the PGE2
enhancement of ATP currents. The role of PKC was also
investigated. We found that bath-application of the mem-
brane-permeant PKC inhibitor, Bis (1 µM), onto the
recorded cell had no effect on the PGE2 action (Figs. 5C
and 5D). Thus, PKC does not participate in the PGE2
modulation of ATP currents in normal DRG neurons.
PGE2 enhances α,β-meATP induced hyperalgesia and 
allodynia
We also determined whether the PGE2 enhancing effect
on P2X3 receptor-mediated responses could be observed
behaviorally (Fig. 6). Low concentrations of α,β-meATP
(1 nmol/50 µl) and PGE2 (0.05 nmol/50 µl) were used
for the study. By keeping the individual effects of either
α,β-meATP or PGE2 small, an enhancing effect of (α,β-
meATP +PGE2), if it existed, could be easily distinguisha-
ble. Intraplantar injection of α,β-meATP or PGE2 lowered
the paw withdrawal (PW) mechanical thresholds by 21.9
± 3.8% and 15.5 ± 3.0% (n = 3) respectively (Fig. 6A).
However, the PW threshold was lowered by 65.3 ± 6.9%
(n = 3) when α,β-meATP and PGE2 were applied simulta-
neously. Thus, the combination of α,β-meATP and PGE2
produced a significantly stronger response than adding
the responses produced by separate application of α,β-
meATP and PGE2. Intraplantar pretreatment with the PKA
inhibitor, H89 (0.5 nmol/50 µl), reversed the enhanced
allodynia produced by PGE2 (Fig 6A). Similar experi-
ments were conducted to study PGE2 effects on the PW
Table 1: Kinetics of ATP-evoked fast-inactivating currents in 
control (Con) and PGE2 treated DRG neurons.
Ta τ1in τ2in
Con 5.9 ± 1.1 38.1 ± 6.6 377.3 ± 95.2
PGE2 5.7 ± 0.9 46.1 ± 7.8 432.3 ± 121.2
Ta: Activation time, i.e., duration between 10 and 90% of peak 
current values.
τ1in and τ2in: Inactivation time constants. Data represent the mean ± 
SEM; n = 15. The differences in Ta, T1in and T2in in Con and PGE2 
neurons were not significant.Molecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
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EP3 receptors mediate the potentiation of ATP responses by PGE2 Figure 3
EP3 receptors mediate the potentiation of ATP responses by PGE2. (A) In the cell shown, PGE2 increased ATP cur-
rents. However, the EP2 receptor-specific agonist, butaprost (Buta) (1 µM), had no effect on the ATP responses. The EP3/EP1 
agonist, sulprostone (Sul) (1 µM) mimicked the enhancing effect of PGE2. The EP1 antagonist, SC-19220 (SC) (1 µM), could not 
block the PGE2 potentiating effect. (B) Bar graphs are the pooled data from 3–8 cells. Only Sul mimicked the PGE2 effect on 
ATP currents. PGE2 effects: 0.1 µM PGE2, IATP (PGE2)/IATP = 1.22 ± 0.04; 1 µM PGE2, IATP (PGE2)/IATP= 1.49 ± 0.06; 10 µM 
PGE2, IATP (PGE2)/IATP = 1.76 ± 0.07. Sul effects: 0.1 µM Sul, IATP  (Sul)/IATP = 1.25 ± 0.06; 1 µM Sul, IATP (Sul)/IATP = 1.52 ± 0.07; 
10 µM Sul, IATP (Sul)/IATP = 1.85 ± 0.08. SC could not inhibit PGE2- or Sul-elicited potentiation. The results suggest that the 
PGE2 effect is mediated by EP3 receptors. (* P < 0.05, # P < 0.01, NS = not significant)Molecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
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Forskolin and 8-Br-cAMP mimic PGE2-elicited increase in ATP currents Figure 4
Forskolin and 8-Br-cAMP mimic PGE2-elicited increase in ATP currents. (A) Effects of forskolin. (Left) Examples of 
the action of forskolin (1 µM, 6 min) or PGE2 (1 µM, 2 min) on fast-inactivating ATP currents in the same cell. (Right) Forskolin 
and PGE2 potentiatied ATP currents (IATP (PGE2)/IATP = 1.45 ± 0.09; IATP (Forskolin)/IATP = 1.52 ± 0.10, n = 5). (B) 8-Br-cAMP 
enhanced ATP currents (IATP (PGE2)/IATP = 1.46 ± 0.08, IATP(8-Br-cAMP)/IATP = 1.55 ± 0.09, n = 4) (*P < 0.05). (C) Forskolin 
occludes the effect of PGE2. In the presence of foskolin, PGE2 could not further increase ATP currents.Molecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
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PKA mediates PGE2-induced increases in ATP responses Figure 5
PKA mediates PGE2-induced increases in ATP responses. (A) Effects of the PKA inhibitor, H89. Treatment with H89 
(1 µM) reduced ATP currents moderately. In the presence of H89, PGE2 could no longer increase ATP currents. The block of 
H89 was reversed rather slowly. After washout of H89 for 35 min, the PGE2 potentiating effect returned to the control levels. 
(B) Effects of the specific membrane impermeant inhibitor PKA-inhibitor (6–22) (PKA-I). PKA-I (0.2 µM) was included in the 
patch pipette. As the result of small diameter tip pipettes used in these experiments, PKA-I did not reach its final concentration 
in the cell interior several minutes after whole cell recording was established. This allowed us to obtain a few control 
responses to PGE2 before PKA-I became effective. With PKA-I, PGE2 no longer potentiated ATP responses. (C) Effects of the 
PKC inhibitor, Bis. Pretreatment of the cell with Bis (1 µM) did not affect the potentiating effect of PGE2. (D) Average effects 
of PGE2, (PGE2+ H89), (PGE2+PKA-I) and (PGE2+Bis). For each protein kinase inhibitor, the effects of PGE2 and (PGE2+ 
inhibitor) were examined in the same cell. For H89, IATP (PGE2-H)/IATP = 1.52 ± 0.08; IATP (PGE2-H+H89)/IATP = 0.94 ± 0.06. 
For PKA-I, IATP (PGE2-P)/IATP = 1.48 ± 0.09; IATP (PGE2-P+PKA-I)/IATP = 0.92 ± 0.05. For Bis, IATP (PGE2-B)/IATP = 1.46 ± 0.07, 
IATP (PGE2-B+Bis)/IATP = 1.42 ± 0.08. Five cells were tested in each group (* P < 0.05, NS = not significant).Molecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
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PGE2 sensitizes the mechanical allodynia and thermal hyperalgesia produced by α,β-meATP Figure 6
PGE2 sensitizes the mechanical allodynia and thermal hyperalgesia produced by α,β-meATP. (A) Mechanical allo-
dynia. Paw withdrawal threshold was measured 10 min after paw injection of α,β-meATP (1 nmol/50 µl) or PGE2 ((0.05 nmol/
50 µl). The data were normalized with baseline responses before either injection. α,β-meATP and PGE2 applied individually 
resulted in a moderate decrease in the threshold [(1-meATP/Con) = 0.22 ± 0.04; (1-PGE/Con) = 0.16 ± 0.03, n = 3)]. How-
ever, co-injection of α,β-meATP and PGE2 produced a much larger decrease in the threshold [1-(meATP+PGE)/Con = 0.65 ± 
0.07, n = 3] than adding the threshold reduction produced by α,β-meATP and by PGE2. H89 (0.5 nmol/50 µl) reversed the 
enhanced allodynia produced by PGE2. (B) Thermal hyperalgesia. α,β-meATP and PGE2, applied separately, produced a small 
reduction in the paw withdrawal latency [(1-meATP/Con) = 0.08 ± 0.04; (1-PGE/Con) = 0.18 ± 0.02, n = 3]. Co-injection of 
PGE2 and α,β-meATP produced a much larger reduction in the paw withdrawal latency [(1-(meATP+PGE)/Con = 0.54 ± 0.04, 
n = 3]. H89 blocked the enhancing effect of PGE2. (* P < 0.05, Two-way ANOVA).Molecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
Page 10 of 13
(page number not for citation purposes)
latency in response to thermal stimulation (Fig. 6B). α,β-
meATP + PGE2 reduced the PW latency significantly more
than the combined reduction of PW latencies produced by
separate application of α,β-meATP and PGE2. H89 again
reversed the enhanced hyperalgesia produced by PGE2.
These observations suggest that PGE2 sensitizes α,β-
meATP-induced allodynia and hyperalgesia through a
PKA signaling pathway.
Discussion
We found that PGE2 increases the amplitude of P2X3
homomeric receptor-mediated ATP currents without
changing the kinetics of the currents in a majority of small
and medium DRG neurons (Fig. 1, Table 1). In contrast,
PGE2 had no effect on P2X2/3 heteromeric receptors. The
enhancement of ATP responses is not due to a change in
the apparent affinity of ATP for P2X3 receptors (Fig. 2) but
the result of activation of PKA by PGE2. The conclusion is
supported by the observations: (1) the PKA activators,
e.g., forskolin, not only mimics the action of PGE2 but
occludes the effect of PGE2 (Fig. 4) and (2) the PKA inhib-
itors, H89 and PKA-I, block the action of PGE2 (Fig. 5).
Our conclusion is further supported by the behavioral
observations that PGE2 sensitizes the α,β-meATP-induced
spontaneous flinching responses [3] and enhances α,β-
meATP-induced allodynia and hyperalgesia (Fig. 6). We
further showed that the enhancement could be blocked
by intraplantar injection of H89 (Fig. 6). The molecular
mechanism responsible for PKA-induced potentiation of
ATP current is not well understood. Few studies were con-
ducted to study the conserved PKA site on the P2X recep-
tor molecules. There is evidence that phosphorylation at
Ser431 in the C-terminus of P2X2 receptors reduces ATP
currents mediated by P2X2 receptors transfected in
HEK293 cells [47]. On the other hand, the adenylyl
cyclase, forskolin, was found to increase ATP currents in
HEK cells expressing P2X4 receptors although the phos-
phorylation site on the receptor has not been identified
[48]. The factor contributing to the differential actions of
PKA on different P2X receptor subtypes has yet to be
determined. It is unclear how phosphorylation of the con-
served PKA site changes P2X receptor activity. A number
of possibilities have been proposed by studying phospho-
rylation of sites other than the PKA site. Phosphorylation
of the PKC sites in P2X1 and P2X2 receptor slowed the
rate of inactivation of ATP currents [49,50]. Calcium/cal-
modulin-dependent protein kinase II was found to
enhance P2X3 receptor activity by promoting trafficking
of the receptor to the membrane [34]. Phosphorylation of
regulatory proteins associated with P2X1 or P2X7 receptor
increased the activity of the P2X receptors [51,52].
To identify the EP receptor involved in the action of PGE2
is challenging because agonists and antagonists of EP
receptors are not completely selective [53]. By using a
combination of the agonists and antagonist, we conclude
that EP3 mediates the potentiating action of PGE2. This
conclusion is consistent with the study of Southall and
Vasko [39] who used reverse transcription polymerase
chain reaction and antisense to identify the EP receptors
participate in PGE2-induced sensitization of DRG neu-
rons. They found that although EP1, 2, 3C and 4 are
expressed in DRG neurons, as observed by others [54],
only EP3C and EP4 receptor subtypes mediate the PGE2-
induced cAMP production and increased release of sub-
stance P and CGRP. We have not determined which EP3
splice variant participates in the potentiating action of
ATP. Given that EP3A and EP3B mRNA are not found in
DRGs [39] and EP3C (i.e., EP3γ) is the only EP3 variant
coupled to Gs to produce cAMP [55], we suggest that
PGE2 acts on EP3C to potentiate the response of P2X3
currents. In addition to increasing ATP currents, PGE2 was
also found to decrease or have no effect on ATP currents
in some DRG neurons. The reason for this variability has
not been studied. DRG neurons expressing other EP recep-
tor subtypes or devoid of EP receptor expression could
contribute to the varying PGE2 actions. For example, the
EP3D receptor is known to couple to Gi or Gq to reduce
cAMP level in cells [45].
It is well documented that PGE2 produces sensitization of
TRPV1 receptors [38] and TTX-resistant Na+  channels
[36,56] in DRG neurons. Here, we show that the P2X3
receptor is another target of PGE2. Since P2X3 receptors
play an important role in pain processing [12,13] and
their activation is sensitive to tissue and nerve injury
[3,11], the modulation by PGE2 would provide a way for
sensory neurons to specifically respond to tissue injury.
Our study elucidates the mechanism of an acute action of
PGE2 on ATP currents. P2X3 receptors have been shown
to undergo profound changes in their expression and traf-
ficking after inflammation and nerve injury [11,31,34].
The binding properties of EP receptors [57] and the sign-
aling of PGE2 can change in inflamed tissues [58-60]. It is
of great interest to determine how PGE2 modulates P2X3
receptor-mediated responses after inflammation or nerve
injury. A good understanding of the plasticity of PGE2
action on P2X receptors under injurious conditions will
help us use the downstream targets of PGE2 for designing
analgesics. Such therapeutic agents should be more spe-
cific and produce less side-effects, thus providing an alter-
native to cyclooxygenase 2 (COX2) inhibitors which can
have devastating risks for patients [61,62].
Conclusion
We demonstrate that PGE2 potentiates P2X3 receptor-
mediated ATP currents in DRG neurons and enhances α,β
meATP-induced allodynia and hyperalgesia by binding to
EP3 receptors to activate the cAMP/PKA signaling cascade.
Thus, the P2X3 receptor represents a downstream target ofMolecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
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PGE2 and is likely a useful therapeutic drug target for
treating inflammatory and neuropathic pain.
Methods
Animals
All animal procedures were in accordance with the guide-
lines of the National Institutes of Health and the Interna-
tional Association for the Study of Pain and approved by
the Institutional Animal Care and Use Committee at the
University of Texas Medical Branch. Sprague Dawley rats
were used in the study. Rats of 25–35 d of age were used
in the electrophysiology study; older rats (8–10 weeks
old) were used in behavioral experiments.
Electrophysiology
ATP currents were recorded from acutely dissociated neu-
rons isolated from L4-5 DRGs of 25–35 d old rats. DRG
neurons isolated from young rats survived better. The
characteristics of ATP currents in young and adult DRGs
were indistinguishable. DRGs were excised from sodium
pentobarbital (50 mg/kg, i.p.) anesthetized rats and put in
an ice-cold, oxygenated dissecting solution, which con-
tained (in mM): 135 NaCl, 5 KCl, 2 KH2PO4, 1.5 CaCl2, 6
MgCl2, 10 glucose, and 10 HEPES, pH 7.2 (osmolarity,
305 mOsm). After removal of the connective tissue, the
ganglia were put into a dissecting solution containing col-
lagenase IV (1.0–1.5 mg/ml; Boehringer Mannheim, Indi-
anapolis, IN) and trypsin (1.0 mg/ml; Sigma, St. Louis,
MO) and incubated for 1 hr at 34.5°C. Afterward, DRGs
were taken out from the enzyme solution, washed and put
into another dissecting solution containing DNAase (0.5
mg/ml; Sigma). Ganglia were then triturated with fire-pol-
ished glass pipettes and the dissociated cells were placed
on acid-cleaned glass coverslips. The experiments were
performed at room temperature two hours after plating.
Cells were continuously superfused (0.5 ml/min) with an
external solution [130 mM NaCl/5 mM KCl/2 mM
KH2PO4/2.5 mM CaCl2/1 mM MgCl2/10 mM HEPES/10
mM glucose, pH 7.3 (osmolarity, 295–300 mosM)]. In
order to obtain a fast solution exchange, ATP (Sigma) was
applied through an electronic valve with a solution
exchange rate of 0.2 ms. This exchange rate was fast
enough so that it would not limit peak ATP responses.
Under voltage-clamp conditions, the whole-cell patch
recording technique was used for current recordings.
Membrane potential was held at -60 mV. Unless indi-
cated, patch-clamp electrodes had a resistance of 3–5
Mohm when filled with the pipette solution, which con-
tained (in mM): 145 K gluconate, 10 NaCl, 10 HEPES, 10
Glucose, 5 BAPTA and 1 CaCl2, pH 7.25 adjusted with
KOH (osmolarity = 290 mOsm). The currents were fil-
tered at 2–5 kHz and sampled at 100 µs per point.
Behavioral experiments
Mechanical allodynia was quantified by the responses to
von Frey filament stimulation using the 50% threshold
methods [63]. Individual rats were placed on a metal
mesh platform and under a plastic dome. Animals were
habituated to the testing environment for at least 20 min
before an experiment. A series of calibrated von Frey fila-
ments of increasing strengths will be applied to the mid-
plantar surface until a paw withdrawal occurred. The 50%
threshold (expressed in grams), which is defined as 10
(Xf+ k × d)/10000 where Xf = value of the final von Frey
filament unit used (in log units); k = tabular value of the
pattern of positive/negative response; d = mean difference
(in log units) between von Frey hairs, was determined. A
cutoff threshold was 15 g to avoid tissue damage. All
behavioral studies were performed under blind condi-
tions. Saline (PBS) or α,β-meATP was injected into the rat
paw. The α,β-meATP effect on PW threshold was meas-
ured 10 min after the injection when the response reached
a peak level. To study the effect of PGE2 on the α,β-meATP
response, α,β-meATP and PGE2 were applied simultane-
ously to the rat paw. To study the protein kinase-depend-
ence of PGE2, the PKA antagonist, H89 was applied 20
min prior to the (PGE2+α,β-meATP) application.
Thermal hyperalgesia was examined by measuring paw
withdrawal latencies (PWLs) using the radiant heat
method [64]. A lamp was placed under the plantar surface
of the rat hindpaw and the time elapsed from the onset of
radiant heat stimulation to the withdrawal of the paw was
recorded. The heat intensity was adjusted to give a base-
line latency of ≈10 s; a cutoff time of 30 s was set to pre-
vent tissue damage. To obtain baseline PWLs, three
measurements separated by a 5-min interval were made
for each rat's hind paw and scores were averaged.
Drugs
Bisindolylmaleimide I (Bis), H89 dihydrochloride (H89),
protein kinase A inhibitor 6–22 amide (PKA-I), were pur-
chased from Calbiochem (La Jolla, CA). ATP, α,β-meATP,
8-Bromoadenosine 3',5'-cyclic monophosphate (8-Br-
cAMP), A-316491 and forskolin were from Sigma (St.
Louis, MO) ; PGE2, sulprostone, butaprost and SC-1220
were from Cayman Chemical (Ann Arbor, MI). Except for
PKA-I, ATP and α,β-meATP, all other compounds were
prepared in DMSO as stocks. The final concentrations
used in experiments at least 1000 times lower than stocks
concentrations. Stock solutions were stored at -20°C and
diluted immediately before use.
Data analyses
All data are expressed as mean ± SEM. Differences
between two means were analyzed with paired or
unpaired Student's t-test. Rise time (Ta) and inactivation
time constants were used to determine kinetic propertiesMolecular Pain 2007, 3:22 http://www.molecularpain.com/content/3/1/22
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of ATP responses. Ta of ATP currents were obtained by
measuring the activation time between 10 and 90% of the
peak value. The time constants of current inactivation
were obtained by fitting the decay phase of current with
exponential functions using the Levenberg-Marquardt
algorithm. Comparisons between multiple means were
done with one-way analysis of variance (ANOVA) fol-
lowed by Newman Keuls post hoc test. A P < 0.05 was con-
sidered significant.
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